ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Rating of “Moderate Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $168.40.

Several research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. BTIG Research assumed coverage on shares of ICU Medical in a research note on Monday, June 15th. They set a “buy” rating and a $170.00 price objective for the company. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Finally, Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 27th.

Insider Transactions at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. Schroder Investment Management Group grew its stake in shares of ICU Medical by 25.2% in the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock worth $93,246,000 after acquiring an additional 160,380 shares during the period. William Blair Investment Management LLC grew its stake in shares of ICU Medical by 9.9% in the third quarter. William Blair Investment Management LLC now owns 232,168 shares of the medical instruments supplier’s stock worth $27,851,000 after acquiring an additional 20,829 shares during the period. Norges Bank bought a new stake in shares of ICU Medical in the fourth quarter worth approximately $58,083,000. Thrivent Financial for Lutherans grew its stake in shares of ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after acquiring an additional 285,648 shares during the period. Finally, Kirr Marbach & Co. LLC IN grew its stake in shares of ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after acquiring an additional 6,863 shares during the period. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Down 0.4%

Shares of ICU Medical stock opened at $148.27 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The company has a 50-day moving average of $131.49 and a 200 day moving average of $138.43. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of 80.15, a PEG ratio of 2.08 and a beta of 0.77. ICU Medical has a 1 year low of $107.00 and a 1 year high of $160.29.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. ICU Medical’s quarterly revenue was down 12.3% compared to the same quarter last year. During the same period last year, the business earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts anticipate that ICU Medical will post 6.5 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.